Secondary analysis of the phase IIb B-Clear trial in chronic hepatitis B: bepirovirsen binding-site SNPs were found at baseline in 7% (22/309) of sequenced participants, who had numerically smaller HBsAg falls; 18% (4/22) still had transient HBsAg loss.
Secondary analysisn = 309
Bouquet et al. Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B